The U.S. FDA approved Phraxis Inc.’s Endoforce Connector for endovascular venous anastomosis, which eliminates the need for surgical dissection for individuals undergoing hemodialysis for kidney ...

Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results impressed Wall Street in head and neck ...

The lack of animal models that mimic human disease impedes the study of many pathologies that still lack treatment beyond symptom relief. This is what has happened so far with PURA syndrome, a rare ...

GSK plc’s Blenrep (belantamab mafodotin) is heading back to the market three years after being withdrawn, with the EMA’s ...

Avenzo Therapeutics Inc. has announced IND clearance by the FDA for AVZO-1418 (DB-1418), an EGFR/HER3 bispecific ...

Interleukin-4 receptor α (IL-4Rα), a shared receptor subunit for both IL-4 and IL-13, along with thymic stromal lymphopoietin ...

Cinclus Pharma Holding AB has chosen Zentiva k.s. to handle manufacturing and commercialization duties in Europe for linaprazan glurate, which is being developed to treat severe erosive ...

Nearly half of the world’s population suffers from allergic rhinitis, meaning that when they inhale allergens from the air, IgE becomes activated and induces paroxysmal sneezing, runny nose and nasal ...

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, as well as autoimmune and inflammatory disorders.

Researchers from Latus Bio Inc. have developed a novel adeno-associated virus (AAV) therapy for treating Huntington’s disease.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has divulged receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of autoimmune ...